As pharma manufacturers strive to demonstrate to payers their products' efficacy in the face of backlash against rising drug prices, one effective tactic may be to enter into value-based contracts. It's crucial for manufacturers to understand how other entities they wish to partner with approach value and to start preparing that value proposition early in the drug development process, AIS Health reported.

Topics: Industry Trends, Market Access, Provider, Payer

According to our recent payer coverage analysis for CLL treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Topics: Specialty, Market Access, Payer, Branding & Marketing

According to our recent payer coverage analysis for atopic dermatitis, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Topics: Specialty, Market Access, Payer, Branding & Marketing

Express Scripts Holding Co. has struck a deal with the manufacturers of Praluent (alirocumab), one of two pricey PCSK9 inhibitors on the market, that will give the PBM a lower net price on the drug in exchange for streamlined patient access and an exclusive spot on the Express Scripts national formulary, AIS Health reported.

 

The pact, unveiled May 1, comes after Regeneron and Sanofi announced in March that they would lower the net price of Praluent for payers willing to reduce access barriers for appropriate patients.

 

Topics: Industry Trends, Market Access, Provider

A survey by EMD Serono, Inc. revealed that managing oncology drugs and services remains the top challenge for health plans, tied with determining the value of specialty drugs and ensuring clinically appropriate use of specialty therapies.

 

Released at the end of April, the 14th edition of the EMD Serono Specialty Digest: Managed Care Strategies for Specialty Pharmaceuticals is based on survey responses from 59 commercial health plans representing more than 76 million covered lives. 

 

Topics: Industry Trends, Market Access, Data & Analytics

According to our recent payer coverage analysis for psoriasis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Topics: Specialty, Market Access, Branding & Marketing

While outcomes-based contracts for prescription drugs are a continual hot topic in the health care industry, experts who spoke on a panel May 1 at the World Health Care Congress cited several barriers that are keeping these contracts from proliferating widely: chiefly, not enough reliable data and regulatory issues such as the federal antikickback statute.

 

"The beautiful thing about value-based contracts is we are basically putting the patient at the center of everything," said Enrique A. Conterno, senior vice president of Eli Lilly and Co.

 

Topics: Industry Trends, Market Access, Payer

According to our recent payer coverage analysis for hypertension treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Topics: Specialty, Market Access, Branding & Marketing

CMS on April 2 finalized new policies in its 2019 Rate Announcement and Final Call Letter for Medicare Advantage (MA) and Part D plans that continue to focus heavily on ways to monitor and decrease opioid misuse, AIS Health reported.

 

To reduce the potential for chronic opioid use or misuse, CMS said that it expects Part D plan sponsors to implement a hard safety edit to limit initial opioid prescription fills for treating acute pain to no more than a seven-day supply. It also requires plan sponsors to implement an opioid care coordination edit at 90 morphine milligram equivalents per day.

 

Topics: Industry Trends, Market Access, Payer

According to our recent payer coverage analysis for asthma and COPD treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Topics: Specialty, Market Access, Branding & Marketing